Incidence and Management of Life-Threatening Adverse Events During Cardiac Catheterization for Congenital Heart Disease by C. Huie Lin et al.
ORIGINAL ARTICLE
Incidence and Management of Life-Threatening Adverse Events
During Cardiac Catheterization for Congenital Heart Disease
C. Huie Lin • Sanjeet Hegde • Audrey C. Marshall • Diego Porras •
Kimberlee Gauvreau • David T. Balzer • Robert H. Beekman III •
Alejandro Torres • Julie A. Vincent • John W. Moore • Ralf Holzer •
Laurie Armsby • Lisa Bergersen
Received: 19 March 2013 / Accepted: 19 June 2013 / Published online: 31 July 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Continued advancements in congenital cardiac
catheterization and interventions have resulted in increased
patient and procedural complexity. Anticipation of life-
threatening events and required rescue measures is a crit-
ical component to preprocedural preparation. We sought to
determine the incidence and nature of life-threatening
adverse events in congenital and pediatric cardiac cathe-
terization, risk factors, and resources necessary to antici-
pate and manage events. Data from 8905 cases performed
at the 8 participating institutions of the Congenital Cardiac
Catheterization Project on Outcomes were captured
between 2007 and 2010 [median 1,095/site (range
133–3,802)]. The incidence of all life-threatening events
was 2.1 % [95 % confidence interval (CI) 1.8–2.4 %],
whereas mortality was 0.28 % (95 % CI 0.18–0.41 %).
Fifty-seven life-threatening events required cardiopulmo-
nary resuscitation, whereas 9 % required extracorporeal
membrane oxygenation. Use of a risk adjustment model
showed that age \1 year [odd ratio (OR) 1.9, 95 % CI
1.4–2.7, p \ 0.001], hemodynamic vulnerability (OR 1.6,
95 % CI 1.1–2.3, p \ 0.01), and procedure risk (category
3: OR 2.3, 95 % CI 1.3–4.1; category 4: OR 4.2, 95 % CI
2.4–7.4) were predictors of life-threatening events. Using
this model, standardized life-threatening event ratios were
calculated, thus showing that one institution had a life-
threatening event rate greater than expected. Congenital
cardiac catheterization and intervention can be performed
safely with a low rate of life-threatening events and mor-
tality; preprocedural evaluation of risk may optimize
preparation of emergency rescue and bailout procedures.
Risk predictors (age \ 1, hemodynamic vulnerability, and
procedure risk category) can enhance preprocedural patient
risk stratification and planning.
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Introduction
Significant advances in transcatheter technologies [1, 19]
have increased the complexity and heterogeneity of con-
genital cardiac catheterization procedures as well as the
complexity and pre-existing morbidity of patients under-
going catheterization. Previous studies of pediatric cardiac
catheterization reported rates of major complications of
0.9–6 % and mortality of 0.14–0.7 %; however, these
reports originated from single-center retrospective studies
with heterogeneous case mixes and data predating tech-
nological advances of the current era [9, 17, 18]. Work
from this group has previously shown the overall rate of
life-threatening adverse events during congenital and
pediatric cardiac catheterization and predictors of these
events [4]. As quality improvement efforts [10], mandatory
registries [14], and appropriate use criteria [15] evolve for
cardiac catheterization, proactive interventionalist-driven
definitions of standards of care have become a priority.
Similarly, necessary resources for hemodynamic support,
transcatheter, and surgical rescue based on preprocedural
risk stratification must be delineated.
The purpose of this study was to use prospectively
collected data from the multicenter Congenital Cardiac
Catheterization Project on Outcomes (C3PO) study to
report the incidence and specific nature of life-threatening
adverse events during congenital catheterization, define
risk factors to anticipate events, and describe the emer-
gency rescue procedures required to manage these events.
In addition, the previously developed Catheterization for
Congenital Heart Disease Adjustment for Risk Method
(CHARM) was applied to report standardized life-threat-
ening event ratios by institution.
Methods
Data were prospectively collected for the C3PO study
beginning on February 1, 2007, at six centers, adding two
additional centers in May 2008 and July 2009 through
January 31, 2010. Participating centers recorded patient
and procedural characteristics and the occurrence of
adverse events using a Web-based data entry tool as pre-
viously described [4]. Boston Children’s Hospital was the
sponsor and data coordinating center for the project. All
diagnostic or interventional catheterizations were included
in the analysis, whereas hybrid procedures and biopsies
were excluded due to the low incidence of life-threatening
events as previously reported [4, 12]. Data collection,
validation, and auditing has previously been reported [4]
and has confirmed accurate and complete capture of serious
adverse events in the database. Established nomenclature
was used to classify adverse event severity ranging from
severity levels 1 to 5 (Supplemental Table 1) as well as
adverse-event preventability (Supplemental Table 2) [2, 5–7,
10, 12]. All events were reviewed by two designated
physicians for proper classification of event severity and
preventability, and any discrepancies with the sites pre-
liminary designation were resolved prospectively during
the study. Life-threatening events were defined as (1)
adverse events related to the catheterization procedure, (2)
identified during or after the procedure resulting in a
change in patient condition, (3) life-threatening if not
treated, (4) requiring major intervention, such as invasive
monitoring or major transcatheter bailout procedure
(severity level 4), and (5) resulting in death and emergency
surgery or failure to wean from extracorporeal membrane
oxygenation (severity level 5, Supplemental Table 1).
Statistical Analysis
The incidence of life-threatening events was calculated for
the study population; frequency and percent were calcu-
lated for adverse event details, type, attributability, sever-
ity, preventability, and management. Patient and
procedural characteristics were compared for subjects with
and without a life-threatening adverse event using Chi
square test for categorical variables and Wilcoxon rank-
sum test for continuous variables.
A multivariable model for the outcome serious adverse
events (levels 3 through 5) has previously been described [8];
three independent predictors are included in CHARM,
namely, age, hemodynamic vulnerability (Supplemental
Table 3) [8], and procedure type risk category (Supplemental
Table 4) [5]. The relationship between these factors and
occurrence of life-threatening adverse events (levels 4 and 5)
was evaluated using logistic regression analysis; odd ratios
(ORs) and 95 % Confidence intervals (CIs) are reported.
The risk-adjusted expected frequencies of life-threaten-
ing events were calculated for each institution using
CHARM [3, 8]. Standardized life-threatening event ratios
were calculated by dividing each institution’s observed
life-threatening event rate by this expected event rate. A
standardized life-threatening event ratio of 1.0 indicated
that the observed event rate is equal to the expected rate
given the institution’s case mix complexity; 95 % CIs were
calculated for each event ratio.
Results
Incidence and Characteristics of Life-Threatening
Events
Between February 2007 to January 2010 (36 months), 8905
cases were captured at 8 sites in the C3PO registry
Pediatr Cardiol (2014) 35:140–148 141
123





event (n = 184) N (%)
or median [IQR]
No life threatening
event (n = 8,721)
N (%) or median [IQR]
P value
Age \0.001
\1 month 45 (25 %) 743 (9 %)
1 to 11 months 53 (29 %) 1920 (22 %)
1 to 10 years 51 (28 %) 3417 (39 %)
C11 years 35 (19 %) 2632 (30 %)
Not recorded 0 (0 %) 9 (\1 %)
Weight (kg) 7 [3.7, 18.7] 14.2 [6.7, 42.3] \0.001
Case Type \0.001
Interventional 147 (80 %) 5692 (65 %)
Diagnostic 37 (20 %) 3029 (35 %)
Diagnosis 0.02
No structural heart disease
(i.e. myopathy)
9 (5 %) 455 (5 %)
Pulmonary hypertension 3 (2 %) 333 (4 %)
Isolated defects 32 (17 %) 2325 (27 %)
Complex defect with two ventricles 81 (44 %) 3435 (39 %)
Complex defect with one ventricle 59 (32 %) 2170 (25 %)
Not recorded 0 (0 %) 3 (\1 %)
Genetic syndrome 23 (13 %) 1216 (14 %) 0.71
Non-cardiac problem 57 (31 %) 2465 (28 %) 0.31
Surgery in prior 30 days 20 (11 %) 531 (6 %) 0.01
Hemodynamic indicators of vulnerability
Mixed venous saturation \60 % two
ventricle or \50 % single ventricle
52 (28 %) 1369 (16 %) \0.001
Systemic ventricle end diastolic
pressure C18 mmHg
21 (11 %) 480 (6 %) 0.002
Systemic arterial saturation \95 %
non-single ventricle or \78 % single
ventricle
88 (48 %) 2747 (32 %) \0.001
Main pulmonary artery pressure systolic
C45 mmHg non-single ventricle, mean
C17mmHg single ventricle
46 (25 %) 1621 (19 %) 0.04
Number of hemodynamic indicators \0.001
0 68 (37 %) 4644 (53 %)
1 49 (27 %) 2336 (27 %)
C2 67 (36 %) 1741 (20 %)
Admission source \0.001
Elective 90 (49 %) 6719 (77 %)
Non-elective 71 (39 %) 1824 (21 %)
Emergent 23 (13 %) 177 (2 %)
Not recorded 0 (0 %) 1 (\1 %)
Transferred on ECMO support 11 (6 %) 128 (1 %) \0.001
Spontaneous respirations 17 (9 %) 2217 (25 %) \0.001
Procedure type risk group \0.001
Group 1 18 (10 %) 2078 (24 %)
Group 2 30 (16 %) 3221 (37 %)
Group 3 60 (33 %) 2051 (24 %)
Group 4 61 (33 %) 1127 (13 %)
Unable to be assigned 15 (8 %) 244 (3 %)
142 Pediatr Cardiol (2014) 35:140–148
123
[median 1,095 cases/site (range 133–3,802)]. During this
period, 188 life-threatening (levels 4 or 5) events occurred
in 184 patients (2.1 %, 95 % CI 1.8–2.4 %). Patient and
procedural characteristics are listed in Tables 1 and 2. In
terms of types of events, 25 % of the life-threatening
events were related to cardiac arrhythmia, 24 % to cardiac
or vascular trauma, 20 % to hemodynamic instability,
13 % to device, coil, stent or other technical issues, 9.5 %
to sedation/anesthesia or airway, 8 % to neurological
complications, air embolus, and pulmonary edema, or other
issues, and 0.5 % to vascular entry site (Fig. 1).
Fifty-seven percent of the cases with life-threatening
events required cardiopulmonary resuscitation (CPR), and
13 % required electrical cardioversion. Nine percent of
patients (n = 16) who experienced life-threatening events
required ECMO support (details in Supplemental Table 5),
and 44 % of these patients (n = 7) ultimately died despite
support. In 10 % of life-threatening events, emergent per-
cutaneous interventions were required, including pericardi-
ocentesis (n = 12), thoracentesis (n = 2), and vessel coil
occlusion (n = 2). Fifteen percent of life-threatening
adverse events required emergent surgery (n = 28) for
management. Reasons for emergent surgery included device
extraction for malposition (n = 1), device embolization
(n = 5) or erosion (n = 3), stent embolization (n = 5),
vessel trauma (n = 5), unconfined vascular tear (n = 3), and
injury to mitral valve structure (n = 2). Attempted surgical
rescue was unsuccessful in 5 patients.
Of the 188 life-threatening events, 25 were catastrophic
(level 5) with an overall procedural mortality rate of
0.28 % (95 % CI 0.18–0.41 %). Event details are listed in
Supplemental Table 6. Of note, 5 deaths resulted from
cardiac perforation during atrial septostomy: 1 adult patient
with end-stage pulmonary hypertension for atrial septal
defect creation with the remaining 4 in neonates with single
or complex two-ventricle physiology and intact atrial septa.
Four other neonates died as a result of unsuccessful atrial
septostomy or pre-existing profound hemodynamic
derangement before transfer despite successful
intervention. Indeed, 10 of the 25 deaths occurred in
patients who were B10 days old.
One death resulted from a pulmonary hypertensive crisis
after successful atrial septal defect creation; one patient
arrested after dissection complicating selective coronary
angiography during transcatheter pulmonic valve implan-
tation; one lung transplant patient with pulmonary vein
stenosis, who was moribund, died from hypotension
degenerating to cardiac arrest after pulmonary venoplasty;
and one patient arrested due to left main coronary stent
thrombosis. One patient died from complications of small-
bowel infarction after embolization of a coil to the superior
mesenteric artery occurred while attempting to coil-occlude
a patent ductus arteriousus stent. Finally, one patient
arrested after aspiration of formula after the procedure and
on postmortem examination was found to have a large
retroperitoneal hemorrhage due to attempted femoral
access. A complete list of cases requiring ECMO are given
in Supplemental Table 5. Cases resulting in death are listed
in Supplemental Table 6.
Preventability of each life-threatening event was clas-
sified by the procedural physician and reviewed during the
described data audit by two independent physicians. Of the
life-threatening events, 10.1 % (n = 19) were classified as
‘‘preventable,’’ suggesting a definite breech of standard
technique or necessary precautions being not taken and
thus that the event was preventable by modification of
technique or care. For example, in one case, air was
inadvertently injected during left ventriculography with air
seen in the anterior sinus of Valsalva, resulting in hypo-
tension and bradycardia with a heart rate approximately 30
beats/min requiring CPR followed by direct current car-
dioversion. After these resuscitation maneuvers, the patient
recovered, and the remainder of the procedure was com-
pleted uneventfully.
In contrast, 47.3 % of cases were classified as ‘‘possibly
preventable’’ (n = 89), whereas 42.6 % of life-threatening
events (n = 80) were classified as ‘‘not preventable,’’ thus
suggesting that no clearly known alteration in method or
Table 1 continued





event (n = 184) N (%)
or median [IQR]
No life threatening
event (n = 8,721)
N (%) or median [IQR]
P value
Inotropic support during the case 87 (47 %) 1121 (13 %) \0.001
Case duration \0.001
\1 hour 23 (13 %) 1916 (22 %)
C1, \3 hours 125 (68 %) 5995 (69 %)
C3, \4 hours 20 (11 %) 590 (7 %)
C4 hours 16 (9 %) 199 (2 %)
Not recorded 0 (0 %) 21 (\1 %)
Contrast dose (cc/kg) 4.5 [2.4, 6.0] 3.3 [1.7, 5.2] \0.001
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care existed to prevent the event. One example of a not-
preventable adverse event involved a critically ill single-
ventricle patient status post-Glenn who arrived in the
catheterization laboratory pulseless and apneic with severe
respiratory acidosis and severe ventricular dysfunction.
Efforts to resuscitate the patient were unsuccessful; how-
ever, a single venogram was performed successfully and
showed no structural abnormality in the Glenn circuit. The
patient subsequently died.
Risk Factors for Life-Threatening Adverse Events
Univariate analysis of possible predictors of life-threatening
adverse events was performed (Table 2) and showed that
age \ 1 year, recent cardiac surgery, C2 hemodynamic
indicators of vulnerability, transfer on ECMO support,
high-risk procedure, and longer case duration were potential
predictors. The multivariable CHARM [8] model was
applied to the outcome ‘‘life-threatening adverse events’’
and the magnitudes of the effect of age \ 1 year, hemo-
dynamic indicators of increased vulnerability, and proce-
dure type risk category estimated (Table 3). Specifically,
children \ 1 year of age undergoing catheterization had
nearly twice the odds of life-threatening events (OR 1.9,
95 % CI 1.4–2.7, p \ 0.001) relative to patients [1 year.
Second, patients C 2 or more indicators of hemodynamic
vulnerability [8] (Supplemental Table 3) had greater odds
of life-threatening events during cardiac catheterization
with an OR of 1.6 (95 % CI 1.1–2.3, p \ 0.01). Third, high-
risk procedures [5] (Supplemental Table 4) were associated
with double and quadruple the odds of life-threatening
events; the OR was 2.3 (95 % CI 1.3–4.1, p = 0.003) for
category 3 procedures and 4.2 (95 % CI 2.4–7.4, p \ 0.001)
for category 4 procedures relative to category 1. Percent of
cases with and without life-threatening events with these
three predictors is plotted in Fig. 2.
Table 2 Predictors of life-
threatening events: univariate
analysis
Predictors (%) No. of patients Life-threatening events
No. of events (%) OR (95 % CI)
Age (years)
\1 2761 98 (3.6) 2.6 (1.9, 3.5)
C1 6135 86 (1.4) 1.0
Diagnosis
No structural heart disease 464 9 (1.9) 1.0
Pulmonary hypertension 336 3 (0.9) 0.5 (0.1, 1.7)
Isolated defects 2357 32 (1.4) 0.7 (0.3, 1.5)
Complex defect with 2 ventricles 3516 81 (2.3) 1.2 (0.6, 2.4)
Complex defect with 1 ventricle 2229 59 (2.7) 1.4 (0.7, 2.8)
Genetic syndrome 1239 23 (1.9) 0.9 (0.6, 1.4)
Noncardiac problem 2522 57 (2.3) 1.1 (0.8, 1.6)
Hemodynamic indicators of vulnerability
0 4712 68 (1.4) 1.0
1 2385 49 (2.1) 1.4 (0.9, 2.1)
C2 1808 67 (3.7) 2.6 (1.9,3.7)
Previous surgery \ 30 days 551 20 (3.6) 1.9 (1.2, 3.0)
Transferred on ECMO support 139 11 (7.9) 4.3 (2.3, 8.0)
Spontaneous respirations 2234 17 (0.8) 0.3 (0.2, 0.5)
Procedure-type risk categories
1 2096 18 (0.9) 1.0
2 3251 30 (0.9) 1.1 (0.6, 1.9)
3 2111 60 (2.8) 3.4 (2.0, 5.7)
4 1188 61 (5.1) 6.2 (3.7, 10.6)
Unable to be assigned 259 15 (5.8) 7.1 (3.5, 14.3)
Case duration (h)
\1 1939 23 (1.2) 1.0
1–3 6120 125 (2.0) 1.7 (1.1, 2.7)
3–4 610 20 (3.3) 2.8 (1.5, 5.2)
[4 215 16 (7.4) 6.7 (3.5, 12.9)
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Life-Threatening Events and Risk Standardization
Eight institutions contributed data with a median of 1,095
cases/site (range 133–3,802); the observed rate of life-
threatening events per site ranged from 0.91 % to 3.27 %.
The expected rates of life-threatening events (calculated
based on CHARM) for each institution ranged from 1.73 to
2.35 % (Table 4). Standardized life-threatening event ratios
(observed event rate/expected event rate) ranged from 0.51
to 1.64 (Fig. 3). One center (institution E) had a signifi-
cantly greater standardized life-threatening event ratio, 1.64
(95 %CI 1.12–2.33). Of the life-threatening events, 6.5 %
were reported as being preventable at this institution; other
institutions reported between 0 and 17.7 % preventable life-
threatening events, whereas the overall rate of preventable
life-threatening events for the study was 10.1 %.
Discussion
This is the first work to describe a large multicenter experi-
ence with life-threatening events in congenital cardiac
catheterization in the contemporary era. We report a low
incidence of life-threatening events (2.1 %) and mortality
(0.28 %) despite the complexity of modern patients and
procedures. The majority of life-threatening events were
treated successfully with CPR, ECMO, surgery, or percuta-
neous bail-out. Nevertheless, there were 25 deaths during the
Fig. 1 Categories of life-threatening adverse events (severity levels 4 and 5) during cardiac catheterization. Percentage and individual event
rates are presented
Table 3 Catheterization for Congenital Heart Disease Adjustment
for Risk Model (CHARM) Predictors and life-threatening adverse
events
Predictors (%) OR (95 % CI) P
Age (years)
\1 1.9 (1.4, 2.7) \0.001
C1 1.0 –
Hemodynamic indicators of vulnerability
0 1.0 –
1 1.0 (0.7, 1.5) 0.87
C2 1.6 (1.1, 2.3) 0.01
Procedure-type risk categories
1 1.0 –
2 0.8 (0.4, 1.5) 0.46
3 2.3 (1.3, 4.1) 0.003
4 4.2 (2.4, 7.4) \0.001
Unable to be assigned 5.7 (2.8, 11.5) \0.001
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study period despite rescue procedures. Predictors of life-
threatening events were age \ 1 year, increased hemody-
namic vulnerability, and high procedure complexity. These
predictors were then used to calculate standardized life-
threatening event ratios, and although most institutions had
an expected rate of life-threatening events based on com-
plexity of case mix, one institution showed a significantly
greater-than-expected rate of events. These operators
reported no greater number of preventable events, suggest-
ing that unmeasured variables may account for the differ-
ence. In sum, the present study defines high-risk patients and
procedures, the nature of life-threatening events, and the
need for appropriate resources to manage these events.
Risk Modeling
Preprocedure risk stratification can now be significantly
enhanced by the development and validation of proce-
dure type risk categories [5] and markers of hemody-
namic vulnerability [8]. Taken together with
age \ 1 year as the third risk predictor, these factors,
which form CHARM, can also serve to inform prepro-
cedure risk. In this manner, patients and families may be
provided with more specific counseling and informed
consent with quantitative estimates of risk. Furthermore,
present findings may be used by procedural teams to
guide preparation for rescue procedures, such as trans-
catheter or surgical bail-out, or mechanical support, such
as ventricular-assist device or ECMO. Third, these cri-
teria can be used to standardize risk between institutions,
operators, or even procedures.
Quality Improvement
Work from this group has proposed the use of CHARM to
provide a method of risk standardization [8] especially with
the emphasis on quality improvement in contemporary
medicine. The present work provides two important find-
ings in this regard. First, the majority of life-threatening
events occurred in the absence of a breach of standard of
care, suggesting that operators did not believe that the
majority of events were preventable, including the insti-
tution with a greater-than-expected rate of life-threatening
events. This raises the important question that current
understanding of standard of care and adverse event pre-
ventability may be insufficiently discriminating or objec-
tive to contribute to the present analysis or quality-
improvement initiatives. In contrast, overall modification
of practice to decrease preventable events may improve
overall outcomes. Second, CHARM may provide a means
for identifying life-threatening events that require more




Fig. 2 Distribution of risk factors for subjects with and without life-
threatening events. a Procedure-type risk category. b Number of
hemodynamic indicators. c Age
Table 4 Standardized life-threatening adverse event ratios for eight
institutions










event ratio (95 %
CI)
A 29 (2.16) 2.01 1.07 (0.72, 1.54)
B 65 (2.08) 2.35 0.89 (0.68, 1.13)
C 15 (1.83) 1.73 1.06 (0.59, 1.74)
D 20 (2.13) 2.09 1.02 (0.62, 1.58)
E 31 (3.27) 1.99 1.64 (1.12, 2.33)
F 16 (1.53) 1.75 0.87 (0.50, 1.42)
G 5 (0.91) 1.79 0.51 (0.16, 1.18)
H 3 (2.17) 1.93 1.12 (0.23, 3.29)
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whereas sick patients undergoing complex procedures may
be ‘‘expected’’ to have life-threatening events, life-threat-
ening events that occur during cases with lower-risk
CHARM characteristics may be ‘‘unexpected’’ and require
a more thorough root cause analysis.
Future efforts should be directed toward decreasing
institutional as well as global standardized life-threatening
event ratio to \1. At least two areas of study may allow
progress toward this goal. First, life-threatening events must
be divided into those occurring in ‘‘expected’’ circumstances
(i.e. sick patient and/or complex procedure) from those
occurring in ‘‘unexpected’’ circumstances (i.e. stable
patients and/or less complex procedures). Efforts can then be
directed toward understanding predictors of emergency
rescue procedures and how they can best be prepared before
or during a high-risk case. For example, should an ECMO
circuit be primed and in the room before or during a case
when high-risk features are identified, or should pre-emptive
support be initiated? Present results suggest that ready
availability and preparation of rescue strategies, including
transcatheter bailout, general, and cardiac surgery, and
availability of ECMO, are a crucial component to manage-
ment of life-threatening events and must be considered a
prerequisite to performing high-risk procedures in high-risk
patients. Similarly, are there patients for whom the risk of
life-threatening events is unacceptable? Although the
answer to this particular question will always be the col-
laborative decision of the care team, the operator, and the
family of the patient, present findings may help to quantify
risk in a manner that better informs this decision.
Second, among patients with unexpected life-threaten-
ing events, specific mechanisms of life-threatening events
(e.g., transseptal puncture and cardiac perforation, device/
coil embolization, etc.) must be studied on a large scale to
understand predictors of successful versus adverse outcome
and how procedures can be modified and optimized. These
future studies will be feasible as more data are acquired
through the efforts of this and other projects such as C3PO-
Quality Improvement (launching in 2013), the Congenital
Cardiovascular Interventional Study Consortium, and the
NCDR/IMPACT registry.
Limitations
Present studies were performed at high- volume centers
with a large base of experience both in transcatheter pro-
cedures as well as general and cardiovascular surgery.
Application of these findings to institutions with hetero-
geneous backgrounds globally will require a nuanced
approach. In addition, due to the low incidence of life-
threatening events during myocardial biopsies [4] and
hybrid procedures [12], these cases were excluded from
this analysis. Finally, although the low mortality rate pre-
cluded a meaningful multivariate analysis of predictors of
death in this study, our report of the descriptive details
herein may assist in hypothesis generation (especially
regarding impact of age of the patient) and development of
additional studies.
Conclusion
When compared with recent results from the Cath PCI/
NCDR registry where in-hospital mortality rate after per-
cutaneous coronary intervention has been reported as
1.27 %, ranging from 0.65 % in elective PCI to 4.81 % in
ST increase myocardial infarction [16], contemporary
congenital cardiac catheterization and intervention is safe
with a low rate of mortality (0.28 %), and life-threatening
events (2.1 %). Although patient and procedural factors
have become more complex in the contemporary era,
findings define the contribution of age, hemodynamic
vulnerability, and procedure type to life-threatening
adverse events. By use of CHARM, preprocedural risk can
Fig. 3 Standardized life-
threatening adverse event ratios
by institution. Standardized life-
threatening adverse event ratios
are plotted by institution
(triangles error bars 95 % CI).
Dashed line indicates observed
life-threatening event
rate = expected rate based on
CHARM
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be quantified and allow objective assessment for need of
rescue procedures and mechanical support. Likewise,
expected outcomes and adverse event rates can be esti-
mated based on this risk model. As such, concern for third-
party scrutiny of morbidity and mortality in outcomes
should not deter qualified operators from performing high-
risk procedures on high-risk patients when clinically indi-
cated in the setting of appropriate preparation of rescue
procedures. Findings from this and future studies should be
applied to appropriately adjust for procedural risk based on
patient and procedural factors.
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